Programme

Jump To:

Pre-conference Workshop | Day 1 | Day 2

Pre-conference Workshop

Time	Topic
09:00 - 12:00	Common Drug Review Workshop Wyatt Health Management
12:00 - 13:00	Lunch
13:00 - 16:00	Product Listing Agreements Workshop Wyatt Health Management
13:00 - 16:00	Product Listing Agreements Workshop PIVINA Consulting

To see the full detailed timed agenda and speaker line up as well as free white papers and reports, download the brochure now

Day 1

Chair:Gregory Glenn, Senior Vice President, JBL Group

Time	Topic
8:30 - 8:45	Registration eyeforpharma team
8:45 - 8:50	Welcome Lanre Ibitoye, Programme Director
8:50 - 8:55	BIOTECanada Opening Address Lynn Buchanan, VP Industry Relations, BIOTECanada
8:55 - 9:00	Words from the event Chair Gregory Glenn, Senior Vice President, JBL Group
9:00 - 9:30	Critical global changes and how to weather impact on the Canadian market Ronnie Miller, CEO and President, Roche Canada
9:30 - 10:00	How new strategies in the rapidly changing private payer market will affect your company Helen Stevenson, CEO, Reformulary Group
10:00 - 10:15	Networking Coffee
10:15 - 10:45	The Great Debate: The impact Comprehensive Economic and Trade Agreement (CETA) on innovative and generic companies Dr. Marc-Andre Gagnon, Research Fellow, Pharmaceutical Research Policy Collaboration
10:45 - 11:15	PANEL: Your potential opportunities and pitfalls in the new provincial and federal political environment Bill Dempster Director, Global Public Affairs Lesia Babiak Chair, Government Affairs Council, Johnson & Johnson Family of Companies in Canada Durhane Wong-Reiger CEO, Canadian Organization of Rare Disorders
11:15 - 11:45	Find your optimum price with the PMPRB Barbara McIsaac, PMPRB litigator, Borden Ladner Gervais
11:45 - 12:30	Networking Lunch
12:30 - 12:45	The relevance of CDR in today's environment George Wyatt, Managing Director, Wyatt Health Management
12:45 - 1:45	The Canadian Agency of Drug and Technologies in Health (CADTH) Update Chander Seghal, Director, Common Drug Review
1:45 - 2:15	Supporting innovation with early input into product development Bob Nakagawa, Assistant Deputy Minister, BC Pharmaceutical Services
2:15 - 2:45	The pharmacists perspective Ben Shenouda, President, Independent Pharmacists of Ontario
2:45 - 3:15	The patient perspective Durhane Wong-Reiger, CEO, Canadian Organization of Rare Disorders Colleen Savage, CEO, Cancer Advocacy Coalition of Canada
3:15 - 3:30	Networking Break
3:30 - 4:00	Understand the impact of Health Canada on your drug pricing and reimbursement strategy David K. Lee, Director of Legislative and Regulatory Modernization, Health Canada
4:00 - 5:00	PANEL: Gain the edge in the private payer market by engaging drug plan sponsors Mike Sullivan, CEO, Cubic Health Bryan Ferguson, Partner, Applied Management Consultants Sherry Adams, Executive Director of HR, City of Brampton Hugh Paton, President, Paton Consulting
5:00 - End	Networking Drinks!

To see the full detailed timed agenda and speaker line up as well as free white papers and reports, download the brochure now

Day 2

Chair:Ben Faienza, Vice President - Market Access and Governmental Affairs, PDCI Market Access

Time	Topic
8:30 - 8:45	Welcome Lanre Ibitoye, Programme Director
8:45 - 9:30	Rx&D International Report 2011: Key Findings Russell Williams, President, Rx&D
9:30 - 10:00	PLAs: A conceptual framework Bob Kamino, President, Canadian Association of Healthcare and Reimbursement
10:00 - 10:45	Partner with the payer: Innovative agreements and payer requirements Representative from Manitoba Health TBC
10:45 - 11:00	Networking Coffee
11:00 - 11:45	Group Negotiation Agreements Wayne Critchley, Senior Consultant, GPA
11:45 - 12:45	Networking Lunch
12:45 - 1:30	The INESSS Update Reiner Banken, Associate Executive Director, INESSS (TBC)
1:30 - 2:15	Round Table Session
2:15 - 2:45	Aligning with a provincial healthcare strategy Steve Long, Executive Director - Pharmaceutical Funding and Guidance, Alberta Health and Welness
2:45 - 3:00	Networking Break
3:00 - 3:30	Biologics and SEBs Mark Fleming, Co-chair, BIOTECanada SEB Taskforce
3:30 - 4:30	PANEL: Key considerations for a reimbursement strategy Doug Grant, SVP - Head of Corporate Affairs, Bayer Healthcare Alain Boisvert, VP Public Affairs, BMS Ilona Torontali, VP Public Affairs, Roche Canada Mark Findlay, VP Access and External Affairs, AstraZeneca
3:30 - 5:00	Rx&D stakeholder information session